Search

Displaying results 8271 - 8280 of 10000 in total
  1. Drug

    Miramistin ion

    go.drugbank.com/drugs/DB19386
    Investigational

    Miramistin ion is under investigation in clinical trial NCT05561816 (Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma).

  2. Drug

    Amitriptylinoxide

    go.drugbank.com/drugs/DB13114
    ApprovedWithdrawn

    Amitriptylinoxide has been used in trials studying Major Depression.

  3. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

  4. Drug

    IK-930

    go.drugbank.com/drugs/DB18149
    Investigational

    IK-930 is an oral, paralog-selective TEAD inhibitor.

  5. Drug

    Ibuproxam

    go.drugbank.com/drugs/DB08955
    ApprovedWithdrawn

    Ibuproxam is a non steroidal anti-inflammatory drug (NSAID).

  6. Drug

    Alimemazine

    go.drugbank.com/drugs/DB01246
    ApprovedVet approvedWithdrawn

    A phenothiazine derivative that is used as an antipruritic.

  7. Drug

    Onvansertib

    go.drugbank.com/drugs/DB15110
    Investigational

    Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

    Synonyms: 1-(2-Hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
  8. Drug

    Iseganan

    go.drugbank.com/drugs/DB16010
    Investigational

    Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).

  9. Drug

    Vixarelimab

    go.drugbank.com/drugs/DB16350
    Investigational

    Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).

  10. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults through post-exposure immunization.